Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
EARLY_PHASE1
3 participants
INTERVENTIONAL
2015-04-30
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
NCT02149173
Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
NCT01916122
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
NCT02409316
18F-fluoroestradiol (FES) PET/CT for Breast Cancer
NCT04883814
[18F]FES PET/.CT in Uterine Cancer
NCT05916196
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Establish the avidity of desmoid tumors on 18F-FES PET/CT imaging. II. Correlate 18F-FES PET avidity with degree of estrogen receptor (ER) expression by immunohistochemistry (IHC).
OUTLINE:
Patients undergo 18F-FES PET/CT imaging over 30 minutes.
After completion of study, patients are followed up for 30 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnostic (18F-FES PET/CT)
Patients undergo 18F-FES PET/CT imaging over 30 minutes.
F-18 16 Alpha-Fluoroestradiol
Undergo 18F-FES PET/CT
Positron Emission Tomography
Undergo 18F-FES PET/CT
Computed Tomography
Undergo 18F-FES PET/CT
Laboratory Biomarker Analysis
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
F-18 16 Alpha-Fluoroestradiol
Undergo 18F-FES PET/CT
Positron Emission Tomography
Undergo 18F-FES PET/CT
Computed Tomography
Undergo 18F-FES PET/CT
Laboratory Biomarker Analysis
Correlative studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not currently on estrogen medication for birth control, menopause, or other reason
* No anti-estrogen therapy for desmoid tumor within the past 6 months
* Both sporadic desmoid tumors and those associated with familial adenomatous polyposis (FAP) syndromes will be included
Exclusion Criteria
* Patients who do not wish to participate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Vanderbilt-Ingram Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ashish Patel
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ashish Patel, MD
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt-Ingram Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Vanderbilt-Ingram Cancer Center, Find a Clinical Trial
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2015-00081
Identifier Type: REGISTRY
Identifier Source: secondary_id
VICC SAR 1458
Identifier Type: OTHER
Identifier Source: secondary_id
VICC SAR 1458
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.